InflaRx (NASDAQ:IFRX) Posts Quarterly Earnings Results, Beats Estimates By $0.18 EPS

InflaRx (NASDAQ:IFRX) issued its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.18, Zacks reports. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.

InflaRx Price Performance

IFRX stock traded down $0.00 during trading on Thursday, reaching $1.28. 78,373 shares of the company were exchanged, compared to its average volume of 215,964. The company has a 50-day moving average of $1.98 and a two-hundred day moving average of $1.91. The company has a market capitalization of $85.86 million, a price-to-earnings ratio of -1.18 and a beta of 1.98. InflaRx has a twelve month low of $1.13 and a twelve month high of $2.82.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of InflaRx in a research report on Friday, March 7th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.